# Expanded Access Program for Asfotase Alfa Treatment for Patients With Infantile- or Juvenile-onset Hypophosphatasia (HPP)

> **NCT02496689** · — · APPROVED_FOR_MARKETING · sponsor: **Alexion Pharmaceuticals, Inc.**

## Conditions studied

- Hypophosphatasia

## Interventions

- **BIOLOGICAL:** asfotase alfa

## Key facts

- **NCT ID:** NCT02496689
- **Lead sponsor:** Alexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** APPROVED_FOR_MARKETING
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2019-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02496689

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02496689, "Expanded Access Program for Asfotase Alfa Treatment for Patients With Infantile- or Juvenile-onset Hypophosphatasia (HPP)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02496689. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*